Cepheid last week reported a 19 percent spike in second-quarter revenues, and said that every one of its Xpert molecular diagnostic tests except influenza demonstrated sequential and year-over-year growth in the quarter.

In addition, executives said they were confident that the manufacturing snafu that plagued the company in the latter half of 2012 has been addressed, although the problem caused a "hangover effect" that negatively impacted Q2 commercial operations and will continue to impact bottom-line performance for the rest of 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.